Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.29

-0.16 (-0.20%)

15:02
10/09/16
10/09
15:02
10/09/16
15:02

Novartis reports Phase 3 data on Tafinlar-Mekinist in melanoma

Novartis announced data from the Phase III COMBI-v study demonstrating an overall survival and a progression-free survival benefit for patients with BRAF V600 mutation-positive advanced melanoma when treated first-line with the combination of Tafinlar and Mekinist compared to vemurafenib monotherapy. The results of the study, which was conducted in 704 patients, are being presented at the European Society for Medical Oncology 2016 Congress. Results from the COMBI-v study found the estimated three-year survival rate to be 45% of patients receiving the combination of Tafinlar + Mekinist compared with 31% of patients who received vemurafenib monotherapy. There were 34 patients who crossed over from the vemurafenib monotherapy arm to the combination arm after the combination demonstrated a significant OS benefit in a prior analysis. Additionally, the estimated three-year progression-free survival rate was 24% for the combination arm and 10%m for the vemurafenib monotherapy arm. At three years of follow up, the combination of Tafinlar + Mekinist continued to demonstrate a benefit on the measures of duration of response and overall response rate, in line with results seen at the two-year follow up analysis. The safety results were consistent with the profile observed to date for the combination and consistent with the profile observed for vemurafenib monotherapy; no new safety concerns were observed.

NVS Novartis
$78.29

-0.16 (-0.20%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

11:17
09/19/17
09/19
11:17
09/19/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIR

AAR Corp.

$36.87

0.32 (0.88%)

11:16
09/19/17
09/19
11:16
09/19/17
11:16
Hot Stocks
AAR Corp. to acquire two MRO facilities from Premier Aviation »

AAR announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NYE

NYSE Market Internals

11:16
09/19/17
09/19
11:16
09/19/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
09/19/17
09/19
11:15
09/19/17
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

BBY

Best Buy

$52.43

-4.92 (-8.58%)

11:13
09/19/17
09/19
11:13
09/19/17
11:13
Technical Analysis
Technical View: Best Buy falls to session lows following outlook »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SIEGY

Siemens

$69.98

0.26 (0.37%)

11:11
09/19/17
09/19
11:11
09/19/17
11:11
Hot Stocks
Siemens, PAS announce partnership to provide monitoring for control systems »

Siemens and PAS Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$58.51

0.395 (0.68%)

11:10
09/19/17
09/19
11:10
09/19/17
11:10
Options
Repeat of bullish option activity in UAL »

Repeat of bullish option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

VIAB

Viacom

$27.32

-0.35 (-1.26%)

, DISCA

Discovery

$21.32

-0.62 (-2.83%)

11:08
09/19/17
09/19
11:08
09/19/17
11:08
Hot Stocks
Cowen sees more trouble ahead for traditional TV names »

Research firm Cowen cut…

VIAB

Viacom

$27.32

-0.35 (-1.26%)

DISCA

Discovery

$21.32

-0.62 (-2.83%)

FOXA

21st Century Fox

$26.50

-0.55 (-2.03%)

DIS

Disney

$98.43

0.325 (0.33%)

CBS

CBS

$57.71

-0.01 (-0.02%)

GOOGL

Alphabet Class A

$929.75

-5.54 (-0.59%)

GOOG

Alphabet

$915.00

-5.29 (-0.57%)

FB

Facebook

$170.01

-1.63 (-0.95%)

NFLX

Netflix

$184.62

2.27 (1.24%)

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 16

    Oct

  • 29

    Nov

XON

Intrexon

$19.19

-0.28 (-1.44%)

11:07
09/19/17
09/19
11:07
09/19/17
11:07
Hot Stocks
Intrexon's Oxitec plans to build centralized mosquito egg production unit »

Oxitec, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRCM

Care.com

$14.45

-0.14 (-0.96%)

11:04
09/19/17
09/19
11:04
09/19/17
11:04
Hot Stocks
Care.com names George Bell to board as lead independent director »

Care.com yesterday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$152.67

1 (0.66%)

11:03
09/19/17
09/19
11:03
09/19/17
11:03
Hot Stocks
M&T Bank enters community-focused strategic partnership with NY Jets »

The New York Jets and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$88.33

-6.25 (-6.61%)

11:02
09/19/17
09/19
11:02
09/19/17
11:02
Hot Stocks
Coordinated Care awarded Commendable Accreditation status from NCQA »

Coordinated Care, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

USB

U.S. Bancorp

$52.64

0.255 (0.49%)

11:01
09/19/17
09/19
11:01
09/19/17
11:01
Hot Stocks
U.S. Bancorp boosts quarterly dividend by 7% to 30c »

U.S. Bancorp said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 17

    Jan

NUVA

NuVasive

$57.80

-0.68 (-1.16%)

11:01
09/19/17
09/19
11:01
09/19/17
11:01
Periodicals
NuVasive mentioned cautiously in short report from GlassHouse Research 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGC

Regal Entertainment

$16.08

-0.365 (-2.22%)

11:00
09/19/17
09/19
11:00
09/19/17
11:00
Conference/Events
Regal Entertainment management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 28

    Sep

  • 02

    Oct

T

AT&T

$37.94

0.515 (1.38%)

11:00
09/19/17
09/19
11:00
09/19/17
11:00
Options
AT&T option volume double normal as implied volatility term structure inverts »

AT&T option volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

KR

Kroger

$21.32

-0.12 (-0.56%)

10:59
09/19/17
09/19
10:59
09/19/17
10:59
Hot Stocks
Kroger outlook revised to Negative from Stable by Fitch »

Fitch affirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

TSLA

Tesla

$385.00

5.19 (1.37%)

10:58
09/19/17
09/19
10:58
09/19/17
10:58
Conference/Events
Tesla management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 02

    Oct

WK

Workiva

$19.75

-0.15 (-0.75%)

10:55
09/19/17
09/19
10:55
09/19/17
10:55
Conference/Events
Workiva to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

BBY

Best Buy

$52.62

-4.7284 (-8.24%)

, AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

10:54
09/19/17
09/19
10:54
09/19/17
10:54
Hot Stocks
Before the Move: Best Buy in focus ahead of first investor meeting in five years »

Shares of Best Buy (BBY)…

BBY

Best Buy

$52.62

-4.7284 (-8.24%)

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

GOOG

Alphabet

$915.00

-5.29 (-0.57%)

GOOGL

Alphabet Class A

$929.75

-5.54 (-0.59%)

BX

Blackstone

$32.51

0.18 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 29

    Nov

VRTX

Vertex

$153.20

-0.41 (-0.27%)

10:52
09/19/17
09/19
10:52
09/19/17
10:52
Hot Stocks
Vertex to present 11 abstracts from CF R&D program at NACFC »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$249.80

0.08 (0.03%)

10:50
09/19/17
09/19
10:50
09/19/17
10:50
Options
Hefty short-term hedge opened in SPYders ETF »

Hefty short-term hedge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.32

0.42 (1.51%)

, AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

10:47
09/19/17
09/19
10:47
09/19/17
10:47
Hot Stocks
Gap rises after Credit Suisse notes improvements in supply chain »

Shares of Gap (GPS)…

GPS

Gap

$28.32

0.42 (1.51%)

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

M

Macy's

$22.29

0.19 (0.86%)

KSS

Kohl's

$46.80

1.905 (4.24%)

JCP

J.C. Penney

$4.16

0.01 (0.24%)

JWN

Nordstrom

$46.73

0.09 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 09

    Nov

UA

Under Armour

$15.67

-0.47 (-2.91%)

, UAA

Under Armour

$17.06

-0.315 (-1.81%)

10:45
09/19/17
09/19
10:45
09/19/17
10:45
Hot Stocks
Athletic gear oversupply worries fuel downgrades of Under Armour, Nike »

Shares of Under Armour…

UA

Under Armour

$15.67

-0.47 (-2.91%)

UAA

Under Armour

$17.06

-0.315 (-1.81%)

NKE

Nike

$53.19

-0.31 (-0.58%)

LULU

lululemon

$59.76

-0.84 (-1.39%)

FINL

Finish Line

$9.88

-0.61 (-5.82%)

FL

Foot Locker

$35.43

-0.83 (-2.29%)

DKS

Dick's Sporting

$27.36

0.01 (0.04%)

HIBB

Hibbett Sports

$13.15

-0.7 (-5.05%)

ADDYY

adidas

$117.60

-0.6 (-0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

SNAP

Snap

$14.72

-0.2 (-1.34%)

, FB

Facebook

$170.01

-1.63 (-0.95%)

10:41
09/19/17
09/19
10:41
09/19/17
10:41
Periodicals
Snapchat signs up more new U.S. users than Instagram in August, Recode says »

Snapchat (SNAP) has…

SNAP

Snap

$14.72

-0.2 (-1.34%)

FB

Facebook

$170.01

-1.63 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.